Orion Oyj
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ORINF research report →
About the company
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. It specializes in central nervous system disorders, oncology, and respiratory diseases. The firm's customers are specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories.
- CEO
- Aino Anna Liisa Hurme
- IPO
- 2013
- Employees
- 3,882
- HQ
- Espoo, FI
Price Chart
- Market Cap
- $11.66B
- P/E
- 19.15
- P/S
- 5.19
- P/B
- 9.03
- EV/EBITDA
- 14.72
- Div Yield
- 2.39%
- Gross Margin
- 64.79%
- Op Margin
- 34.11%
- Net Margin
- 27.12%
- ROE
- 48.73%
- ROIC
- 35.37%
- Revenue
- $1.89B · 22.50%
- Net Income
- $500.30M · 51.65%
- EPS
- $3.56 · 52.14%
- Op Income
- $629.00M
- FCF YoY
- 6.15%
- 52W High
- $82.75
- 52W Low
- $48.65
- 50D MA
- $82.75
- 200D MA
- $81.35
- Beta
- 0.29
- Avg Volume
- 58.8
Get TickerSpark's AI analysis on ORINF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our ORINF coverage
Recent articles, reports, and earnings notes.
No research on ORINF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ORINF report →Similar companies
Peers in the same neighborhood.